Laura Francis Sells 5,412 Shares of SI-BONE, Inc. (NASDAQ:SIBN) Stock

SI-BONE, Inc. (NASDAQ:SIBN) CEO Laura Francis sold 5,412 shares of the stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $19.49, for a total value of $105,479.88. Following the completion of the transaction, the chief executive officer now directly owns 490,987 shares of the company’s stock, valued at $9,569,336.63. This represents a 1.09% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Laura Francis also recently made the following trade(s):

• On Friday, May 16th, Laura Francis sold 12,385 shares of SI-BONE stock. The stock was sold at an average price of $19.67, for a total value of $243,612.95.
• On Wednesday, May 7th, Laura Francis sold 38,504 shares of SI-BONE stock. The shares were sold at an average price of $17.18, for a total value of $661,498.72.

SI-BONE Trading Down 3.0%

NASDAQ:SIBN opened at $19.12 on Thursday. The company has a market cap of $814.80 million, a PE ratio of -20.78 and a beta of 0.82. The business’s 50 day moving average is $15.11 and its two-hundred day moving average is $15.14. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. SI-BONE, Inc. has a 52 week low of $11.70 and a 52 week high of $20.05.

SI-BONE (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.09. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The firm had revenue of $47.29 million for the quarter, compared to analysts’ expectations of $45.13 million. On average, analysts predict that SI-BONE, Inc. will post -0.78 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. American Century Companies Inc. lifted its holdings in SI-BONE by 11.1% in the first quarter. American Century Companies Inc. now owns 2,642,322 shares of the company’s stock worth $37,072,000 after acquiring an additional 264,254 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of SI-BONE by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 2,444,159 shares of the company’s stock worth $34,292,000 after purchasing an additional 35,349 shares during the last quarter. Silvercrest Asset Management Group LLC boosted its position in SI-BONE by 21.9% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 1,953,806 shares of the company’s stock valued at $27,392,000 after purchasing an additional 350,970 shares during the period. First Light Asset Management LLC grew its stake in SI-BONE by 41.8% during the 1st quarter. First Light Asset Management LLC now owns 1,612,408 shares of the company’s stock worth $22,622,000 after buying an additional 475,426 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY grew its stake in SI-BONE by 5.3% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 1,386,031 shares of the company’s stock worth $19,432,000 after buying an additional 69,831 shares during the last quarter. 98.11% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on SIBN shares. Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 price target on shares of SI-BONE in a research note on Tuesday, May 6th. Truist Financial raised their price objective on shares of SI-BONE from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, May 6th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $24.00 target price on shares of SI-BONE in a research report on Tuesday, May 6th.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.